Andere Sprachen Apontis Pharma AG

Aktien

A3CMGM

DE000A3CMGM5

APPH

Markt geschlossen - Xetra Andere Börsenplätze 17:36:18 08.05.2024			Nachbörslich 18:23:36
8,66 ^EUR	+3,59 %		8,66	0,00 %

15.04.	Börse Frankfurt-News: Längst nicht jeder schwächelt (Scale-Marktbericht)	DP
28.03.	Apontis Pharma AG berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Apontis Pharma : Earnings Call Q1/24 Presentation	17:42
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed	07:34
Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	05.04.
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	05.04.
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	05.04.
Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
APONTIS PHARMA expects profitable growth again in 2024	28.03.
Apontis Pharma : Earnings Call 2023 Presentation	28.03.
APONTIS PHARMA successfully completes performance and efficiency improvement program	06.02.
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	09.11.
Apontis Pharma Provides Earnings Guidance for the Full Year 2023	09.11.
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program	08.11.
Apontis Pharma AG Reports Earnings Results for the Half Year Ended June 30, 2023	11.08.23
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline	10.08.23
AstraZeneca Cancels Lung Disease Drug Co-promotion Deal With Apontis Pharma	01.08.23
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024	31.07.23
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched	27.07.23
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026	27.07.23
Apontis Pharma CEO Steps Down; New Chief to Start September	10.07.23
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor	10.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Apontis Pharma AG

Aktien

A3CMGM

DE000A3CMGM5

APPH

Andere Sprachen

Filter